Ventricular Dysfunction, Left
Recent clinical, regulatory, research and industry developments relating to this disease.
Cardiac Involvement in a Patient With Coronavirus Disease 2019 (COVID-19).
The effect of cardiac resynchronization on morbidity and mortality in heart failure.
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
Therapeutic landscape
Therapies with a regulatory footing for this condition, alongside the wider set of agents co-studied with it in the literature.
Approval — Multaq is indicated for the maintenance of sinus rhythm after successful cardioversion in… (2009)
Clinical trials
The current development programme across all trial phases.
Regulatory timeline
Drug regulatory events matched to this condition by indication — EMA.
European Medicines Agency (CC BY 4.0). Events are matched to this condition by drug indication text — approvals/updates for drugs indicated for it, not disease-specific acts.
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Major themes8
- Cardiac Pacing, Artificial2
- Heart Failure2
- Pacemaker, Artificial2
- Ventricular Dysfunction, Left2
- Amyloidosis1
- Angiotensin Receptor Antagonists1
- Atrial Fibrillation1
- Betacoronavirus1
Leading journals6
- JAMA3
- JAMA cardiology3
- European heart journal2
- European heart journal. Cardiovascular Imaging2
- The New England journal of medicine2
- Circulation1
Leading researchers8
- Flachskampf FA3
- Solomon SD3
- Appleton CP2
- de Boer RA2
- Desai AS2
- Docherty KF2
- Gillebert TC2
- Hernandez AF2
Affiliations (unnormalised)6
- Brigham and Women's Hospital4
- Cleveland Clinic2
- Mayo Clinic2
- Methodist DeBakey Heart and Vascular Center2
- Northwestern University Feinberg School of Medicine2
- Washington University School of Medicine2
Related conditions
Diseases frequently studied alongside this one. Number shows shared papers.
Disease profile
A grounded synthesis of the condition — overview, causes, mechanism, risk factors and current standard of care.
Left ventricular dysfunction is a condition in which the left ventricle is functionally impaired. It is typically identified by a reduced ejection fraction and depressed left ventricular wall motion, and it is associated with cardiovascular complications such as heart failure and myocardial infarction.
The literature grounding describes impaired left ventricular function in terms of reduced stroke volume, abnormal ventricular function, altered diastolic performance, and hemodynamic impairment. Echocardiographic measures such as ejection fraction, wall motion, and global longitudinal strain are used to detect diminished systolic performance and early subclinical dysfunction.
Potentially cardiotoxic chemotherapy is associated with subclinical left ventricular dysfunction and cancer therapy-related cardiac dysfunction. Heart failure populations with reduced, mildly reduced, or preserved ejection fraction are also a major clinical context in which left ventricular dysfunction is studied.
Management is described at the class level in heart failure literature, including SGLT-2 inhibitors for patients with heart failure, especially those with reduced ejection fraction. Echocardiography-based chamber quantification and myocardial deformation imaging are used for assessment and monitoring, including detection of early dysfunction.
AI-generated summary grounded in MeSH and 3 peer-reviewed sources. Informational only — not medical advice. Generated 2026-07-07.
Reference
Authoritative identity, definition & identifiers.
A condition in which the LEFT VENTRICLE of the heart was functionally impaired. This condition usually leads to HEART FAILURE; MYOCARDIAL INFARCTION; and other cardiovascular complications. Diagnosis is made by measuring the diminished ejection fraction and a depressed level of motility of the left ventricular wall.
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.